Fig. 5: Venetoclax combined with chiglitazar preferentially targets CD34⁺ AML cells in vivo.

A Primary AML cells were exposed to venetoclax (50 nM) or chiglitazar (10 μM) alone or in combination for 24 h, then apoptosis and survive were measured using flow cytometric analysis and CCK-8 assays (n = 22). B Healthy donors HSC cells (n = 9). *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.